Background: Dementia is one of the milestones of advanced Parkinson's disease (PD), with its neuropathological substrate still being a matter of debate, particularly regarding its potential mechanistic implications. Objective: The aim of this study was to review the relative importance of Lewy-related α-synuclein and Alzheimer's tau and amyloid-β (Aβ) pathologies in disease progression and dementia in PD. Methods: We reviewed studies conducted at the Queen Square Brain Bank, Institute of Neurology, University College London, using large PD cohorts. Results: Cortical Lewy- and Alzheimer-type pathologies are associated with milestones of poorer prognosis and with non-tremor predominance, which have been, in turn, linked to dementia. The combination of these pathologies is the most robust neuropathological substrate of PD-related dementia, with cortical Aβ burden determining a faster progression to dementia. Conclusion: The shared relevance of these pathologies in PD progression and dementia is in line with experimental data suggesting synergism between α-synuclein, tau and Aβ and with studies testing these proteins as disease biomarkers, hence favouring the eventual testing of therapeutic strategies targeting these proteins in PD.

1.
Hely MA, Reid WG, Adena MA, et al: The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008;23:837-844.
2.
McKeith IG, Dickson DW, Lowe J, et al: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-1872.
3.
Evans J, Revesz T, Barker RA: Lesions associated with cognitive impairment and dementia; in Halliday G, Barker RA, Rowe D: Non-Dopamine Lesions in Parkinson's Disease. Oxford, Oxford University Press, 2011.
4.
Pletnikova O, West N, Lee MK, et al: Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging 2005;26:1183-1192.
5.
Lashley T, Holton JL, Gray E, et al: Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients. Acta Neuropathol 2008;115:417-425.
6.
Clinton LK, Blurton-Jones M, Myczek K, et al: Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 2010;30:7281-7289.
7.
Guo JL, Covell DJ, Daniels JP, et al: Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell 2013;154:103-117.
8.
Blennow K, Hampel H: CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605-613.
9.
Fagan AM, Mintun MA, Mach RH, et al: Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006;59:512-519.
10.
Tokuda T, Qureshi MM, Ardah MT, et al: Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010;75:1766-1772.
11.
Selikhova M, Williams DR, Kempster PA, et al: A clinico-pathological study of subtypes in Parkinson's disease. Brain 2009;132:2947-2957.
12.
Kempster PA, O'Sullivan SS, Holton JL, et al: Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain 2010;133:1755-1762.
13.
Compta Y, Parkkinen L, O'Sullivan SS, et al: Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain 2011;134:1493-1505.
14.
Braak H, Del Tredici K, Rüb U, et al: Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
15.
Braak H, Alafuzoff I, Arzberger T, et al: Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol (Berlin) 2006;112:389-404.
16.
Halliday G, Hely M, Reid W, Morris J: The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 2008;115:409-415.
17.
Sabbagh MN, Adler CH, Lahti TJ, et al: Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord 2009;23:295-297.
18.
Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK: Striatal beta-amyloid deposition in Parkinson disease with dementia. J Neuropathol Exp Neurol 2008;67:155-161.
19.
Irwin DJ, White MT, Toledo JB, et al: Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 2012;72:587-598.
20.
Kotzbauer PT, Cairns NJ, Campbell MC, et al: Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia. Arch Neurol 2012;69:1326-1331.
21.
Compta Y, Martí MJ, Ibarretxe-Bilbao N, et al: Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov Disord 2009;24:2203-2210.
22.
Petrou M, Bohnen NI, Müller ML, et al: β-Amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology 2012;79:1161-1167.
23.
Compta Y, Ibarretxe-Bilbao N, Pereira JB, et al: Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia. Parkinsonism Relat Disord 2012;18:941-947.
24.
Shimada H, Shinotoh H, Hirano S, et al: β-Amyloid in Lewy body disease is related to Alzheimer's disease-like atrophy. Mov Disord 2013;28:169-175.
25.
Siderowf A, Xie SX, Hurtig H, et al: CSF amyloid-beta 1-42 predicts cognitive decline in Parkinson disease. Neurology 2010;75:1055-1061.
26.
Compta Y, Pereira JB, Ríos J, et al: Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study. Parkinsonism Relat Disord 2013;19:717-724.
27.
Prikrylova Vranova H, Mares J, Hlustik P, et al: Tau protein and beta-amyloid(1-42) CSF levels in different phenotypes of Parkinson's disease. J Neural Transm 2012;119:353-362.
28.
Müller ML, Frey KA, Petrou M, et al: β-Amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia. Mov Disord 2013;28:296-301.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.